Hikma Pharmaceuticals PLC ADR (HKMPY PINK) stock market data APIs
$51.0547
0(0%)
as of April 25, 2025
Hikma Pharmaceuticals PLC ADR Financial Data Overview
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Prev. Close
51.0547
Open
51.0547
High
51.0547
Low
51.0547
52 wk Range
44.9205-57.7396
Market Cap
5 649 M
P/E Ratio
15.9161
Shares Outstanding
110 M
Revenue
3 127 M
Dividends (Yield)
0.0312
Beta
0.687
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hikma Pharmaceuticals PLC ADR data using free add-ons & libraries
Get Hikma Pharmaceuticals PLC ADR Fundamental Data
Hikma Pharmaceuticals PLC ADR Fundamental data includes:
- Net Revenue: 3 127 M
- EBITDA: 787 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-25
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hikma Pharmaceuticals PLC ADR News
New
Stocks to watch next week: Tesla, Alphabet, Intel, Boeing and Unilever
As the latest earnings season gets well underway, there are a range of big-name companies due to report in the coming week. Two Magnificent 7 companies are reporting next week, with Elon Musk's Tesla...
Hikma acquires Novugen's FDA-approved ANDA for trametinib
LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (...
With 57% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backing
Key Insights Given the large stake in the stock by institutions, Hikma Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 12 investors have a majority stake in the...
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and GAITHERSBURG, Md....
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
